相关临床试验
4102
519 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1948
终止
480
11.7%
招募中
343
8.4%
暂停
31
0.8%
撤回
112
2.7%
进行中（未招募）
460
11.2%
Unknown
14
0.3%
已完成
2603
63.5%
Enrolling By Invitation
16
0.4%
尚未招募
43
1.1%
暂无批准数据
- Longeveron's ELPIS II Phase 2b trial of laromestrocel in 40 infants with hypoplastic left heart syndrome missed its primary endpoint of change in right ventricular ejection fraction at 12 months. - The intent-to-treat least-squares mean difference in RVEF was -0.7 percentage points (95% CI: -7.3 to 5.9; p=0.8336), and a sponsor-defined hierarchical composite endpoint was also not statistically significant. - Laromestrocel showed a safety profile consistent with prior trials, with no new safety signals and no treatment-emergent adverse events assessed by investigators as related to the therapy. - Longeveron plans to discuss the complete dataset with the FDA and has initiated a review of all strategic options, including cash conservation measures, to maximize shareholder value.
- The FDA held a public hearing on the future therapeutic use of psychedelics, drawing more than 1,800 registered attendees and roughly 80 scheduled speakers. - The hearing followed the agency's July 2026 finalized guidance on psychedelic clinical investigations and an April executive order aimed at accelerating access. - Speakers clashed over provider credentialing, patient safety, rural access, and the need for standardized adverse event and outcome data. - FDA's public docket remains open through October 5, 2026, and written comments will inform continued federal coordination on psychedelic drug development.
- UC Davis investigators have launched WE-CAIR, a multidisciplinary program to study how wildfire smoke drives cardiovascular and airway inflammation over the short and long term. - The initiative is backed by a five-year NIH Program Project Grant (P01 HL179398) from the National Heart, Lung, and Blood Institute totaling $14,050,840, including $8,993,941 in direct costs. - Four integrated projects will probe ILC2 immune cells, the aryl hydrocarbon receptor, the epigenetic regulator TET1, and the role of psychosocial stress and social vulnerability. - Studies estimate the number of people exposed to at least one day of extreme wildfire smoke annually has increased 27-fold over the past decade.
- A multi-institutional team discovered MWAC-3634, a small molecule that blocks Ebola virus entry by stabilizing the viral entry protein rather than destabilizing it. - Screened from roughly 4.73 billion molecules using DNA-encoded chemistry, the compound inhibited authentic Ebola virus with an IC50 of 0.65 nM. - In a lethal mouse model, 85.7% of orally treated mice survived versus 28.6% of controls, with 100% survival among injected mice. - MWAC-3634 showed 69% oral bioavailability, but researchers caution it remains experimental and has not been tested or approved for human use.
- The NIH has awarded a first installment of $4.6 million, part of up to $12.8 million over three years, to a multi-university team modeling drug-hormone interactions in women. - Thirteen researchers from Michigan State, Rutgers, Emory, Tulane, and other institutions will build computational models integrating age and reproductive cycle stage into drug predictions. - The project targets metabolic drugs such as metformin, insulin, and GLP-1 agents, whose effects may vary with shifting female hormone levels. - All computer models and data will be freely available worldwide, with findings intended to inform NIH guidelines and national safety standards.
- A Nature study presents the first genomic analysis of eight Myotis bat species, linking longer lifespans to stronger immune defense and cancer-suppressing gene activity. - Cells from the little brown bat responded to lethal chemical damage by activating cell-death genes rather than DNA repair, mirroring the elephant's anti-cancer strategy. - Researchers found far more overlap than expected by chance between genes associated with bat longevity and genes involved in bat-virus interactions. - Myotis bats show unusual enrichment of genes interacting with DNA viruses such as herpesviruses, a pattern opposite to humans and other primates.
- Salk Institute researchers identified a mitochondria-centered pathway in which chronic interferon II exposure causes melanoma cells to produce prostaglandin E2 and suppress immune attack. - In mouse melanoma models, blocking prostaglandin E2 synthesis restored immune recognition of tumors and reversed anti-PD1 resistance, with complete regression in nine of 10 mice. - The pathway links mitochondrial RNA release to cyclooxygenase 2 activity, explaining how interferons shift from anti-cancer to pro-cancer signaling over time. - Published in Science on September 10, 2026, the findings point to prostaglandin E2 blockade as a potential strategy against immunotherapy resistance.
- The National Institutes of Health has awarded a $26 million grant to Rhode Island's statewide clinical and translational research hub to fund its next five years of work. - The National Institute of General Medical Sciences issued the award on Sept. 3 to Brown University, the host institution for the Advance RI-CTR program. - Advance RI-CTR, launched in 2016, supports biomedical and public health scholars working to translate scientific discoveries into patient care improvements. - The program is a partnership spanning Brown University, the University of Rhode Island, Brown University Health, Care New England, the V.A. Providence Healthcare System and community organizations.
- The CDC is establishing an Early Life Exposure Research Center to study health effects in people aged 21 or younger when exposed to 9/11 contaminants. - About 40,000 children lived in Lower Manhattan during the attacks, yet no systematic study has tracked their long-term health outcomes. - The youth cohort stems from a December 2022 Congressional mandate, following a 2022 amendment expanding the WTC program's eligible cohort. - More than 1,500 scientific publications have documented 9/11 health effects, but only a small percentage focused on early-life exposure.
- The Senate Special Committee on Aging will convene Congress' first-ever hearing devoted to menopause on Sept. 16, led by ranking member Sen. Kirsten Gillibrand. - Women's health research accounted for just 7.9 percent of total NIH funding in 2023, and closing the gap would require an additional $15.71 billion over five years. - Researchers have documented that women report adverse drug reactions 52 percent more often than men, with serious or fatal reactions occurring 36 percent more often since 2000. - Exercise physiology research shows menstrual cycle phase and hormonal birth control have no significant effect on blood vessel function, undermining a long-cited rationale for excluding women.
